Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .
Transcatheter aortic valve implantation using the ACURATE TA™ system: 1-year outcomes and comparison of 500 patients from the SAVI registries
Abstract OBJECTIVES : The ACURATE TATM system is a self-exp and ing transcatheter heart valve system design ed for transapical access which has been proven to be safe and effective in the controlled setting of clinical trials . The SAVI-1 and SAVI-2 registries aim ed to assess whether these promising outcomes can be translated into all-comers clinical routine . METHODS : From November 2011 to 2012 ( SAVI-1 ) , and November 2013 to 2014 ( SAVI-2 ) , a total of 500 patients were enrolled in the prospect i ve , all-comers , multicentre , multinational SAVI registries . Patients were treated according to the st and ard of care at their respective hospitals . We report and compare 30-day and 1-year clinical outcomes between SAVI-1 and -2 . RESULTS : Patients were 80.8 ± 6.1 years old , the mean logistic EuroSCORE-I was 23.4 ± 14.3 % . Valves were deployed under rapid pacing in 71.3 % of the procedures in SAVI-1 , and in 3.6 % in SAVI-2 . There was no relevant difference in clinical and echocardiographic outcomes between SAVI-1 and SAVI-2 . Overall mortality at 30 days and 1 year was 6.8 % and 19.9 % , the stroke rate was 2.2 % and 3.7 % , respectively ; 10.2 % of patients had received a permanent pacemaker , and no transcatheter valve-related complications after discharge were observed . Paravalvular leakage ≥2 + was reported in 1.9 % of the patients at the early follow-up , and in 2.6 % at the 1-year follow-up . CONCLUSIONS : The SAVI-registries have confirmed that transapical implantation using the ACURATE TATM device is safe and effective in an all-comers setting with low complication rates and stable performance outcomes at short-term and 1 year ; outcomes were similar between SAVI-1 and -2 . Clinical Trials.gov :
Specific recommendations for implantation of each prosthesis , taking into consideration the presence of pre-existent conduction abnormalities and anatomical factors , may be needed to reduce the risk of PPI
Aims The incidence of new-onset conduction abnormalities requiring permanent pacemaker implantation ( PPI ) after transcatheter aortic valve implantation ( TAVI ) with new-generation prostheses remains debated .
This systematic review analyses the incidence of PPI after TAVI  with new-generation devices and evaluates the electrical , anatomical , and procedural factors associated with PPI .
In addition , the incidence of PPI after  TAVI with early generation prostheses was review ed for comparison .